₹1,370.55-2.75 (-0.20%)
12-Dec-2025₹1,369.80-0.40 (-0.03%)
12-Dec-2025BSE : 543960
NSE : CONCORDBIO
Sector : Health care
ISIN Code : INE338H01029
Last Updated: 12-Dec-2025
| Market Cap (₹ Cr) | 14,336 |
Traded Value (₹ Cr) | 0.32 |
Volume (Shares) | 2,302 |
Face Value (₹) | 1 |
52-Week High (₹) | 2,451.65 |
52-Week High Date | 10-Feb-2025 |
52-Week Low (₹) | 1,334.50 |
52-Week Low Date | 09-Dec-2025 |
All Time High (₹) | 2,658.00 |
All Time High Date | 20-Sep-2024 |
All Time Low (₹) | 900.00 |
All Time Low Date | 18-Aug-2023 |
| PARAMETER | VALUES |
|---|---|
| Market Cap (₹ Cr) | 14,328 |
| EPS - TTM (₹) [C] | 30.92 |
| P/E Ratio (X) [C] | 44.30 |
| Face Value (₹) | 1 |
| Latest Dividend (%) | 1,070.00 |
| Latest Dividend Date | 03-Sep-2025 |
| Dividend Yield (%) | 0.64 |
| Book Value Share (₹) [C] | 174.68 |
| P/B Ratio (₹) [C] | 7.84 |
| Scheme Name | Amount Invested (₹ Cr) | No Of Shares | Net Asset (%) |
|---|---|---|---|
| DSP Small Cap Fund (G) | 130.48 | 9,20,427 | 0.77 |
| DSP Small Cap Fund (IDCW) | 130.48 | 9,20,427 | 0.77 |
| DSP Small Cap Fund - Direct (IDCW) | 130.48 | 9,20,427 | 0.77 |
| DSP Small Cap Fund - Direct (G) | 130.48 | 9,20,427 | 0.77 |
| SBI Healthcare Opportunities Fund (IDCW) | 102.07 | 7,20,000 | 2.47 |
| SBI Healthcare Opportunities Fund (G) | 102.07 | 7,20,000 | 2.47 |
| SBI Healthcare Opportunities Fund - Direct (G) | 102.07 | 7,20,000 | 2.47 |
| SBI Healthcare Opportunities Fund - Direct (IDCW) | 102.07 | 7,20,000 | 2.47 |
| HSBC Small Cap Fund (G) | 83.88 | 5,91,730 | 0.52 |
| HSBC Small Cap Fund (IDCW) | 83.88 | 5,91,730 | 0.52 |
Load more
| Date | Broker | Action | Prices(₹) | Report |
|---|---|---|---|---|
| Data Not Found | ||||
| Today's Low/High (₹) | 1,354.60 1,384.40 |
| Week Low/High (₹) | 1,334.20 1,430.00 |
| Month Low/High (₹) | 1,334.20 1,510.00 |
| Year Low/High (₹) | 1,334.20 2,452.00 |
| All time Low/High (₹) | 900.00 2,664.00 |
| Period | BSE | NSE | SENSEX | NIFTY |
|---|---|---|---|---|
| 1 Week | -2.44% | -2.74% | -0.52% | -0.53% |
| 1 Month | -6.36% | -6.38% | 0.95% | 0.66% |
| 3 Month | -16.22% | -16.42% | 4.11% | 3.71% |
| 6 Month | -33.51% | -33.62% | 4.38% | 4.66% |
| 1 Year | -35.88% | -36.06% | 4.89% | 6.10% |
| 3 Year | - | - | 37.24% | 40.82% |
Chairman / Executive Director / M D / Promoter : SUDHIR JAIRAM VAID
ED / Joint MD / CEO / Promoter : ANKUR VAID
Non Executive Director : Ravi Kapoor
Non Executive Director : Rajiv Agarwal
Independent Non Exe. Director : BHARTI KHANNA
Independent Non Exe. Director : Amitabh Thakore
Independent Non Exe. Director : Arvind Agarwal
Independent Non Exe. Director : Jayaram Easwaran
Independent Non Exe. Director : Mandayam Chakravarthy Sriraman
Company Sec. & Compli. Officer : Hina Ronak Patel
Registered Office: 1482-86 Trasad Road, Dholka,Ahmedabad,Gujarat-382225 Ph: 91-079-68138700
1. What's the Concord Biotech Ltd share price today?
Concord Biotech Ltd share price was Rs 1,370.55 at close on 12th Dec 2025. Concord Biotech Ltd share price was down by 0.20% from the previous closing price of Rs 1,373.30. Concord Biotech Ltd share price trend:
2. How can I quickly analyse the performance of the Concord Biotech Ltd stock?
The performance of the Concord Biotech Ltd stock can be quickly analysed on the following metrics:
3. What is the market cap of Concord Biotech Ltd?
Concord Biotech Ltd has a market capitalisation of Rs 14,336 crore.
4. What is Concord Biotech Ltd's 52-week high/low share price?
The Concord Biotech Ltd’s 52-week high share price is Rs 2,451.65 and 52-week low share price is Rs 1,334.50.
5. Is the Concord Biotech Ltd profitable?
On a consolidated basis, Concord Biotech Ltd reported a profit of Rs 63.06 crore on a total income of Rs 262.70 crore for the quarter ended 2025.
6. Which are Concord Biotech Ltd’s peers in the Health care sector?
Concord Biotech Ltd’s top 5 peers in the Health care sector are Alembic Pharma, Natco Pharma, Caplin Point Lab, Concord Biotech, Granules India, Acutaas Chemical, Alivus Life.
7. Who owns how much in Concord Biotech Ltd?
Key changes to the Concord Biotech Ltd shareholding are as follows: